FDA Approves Durvalumab Plus BCG for High-Risk Non-Muscle Invasive Bladder Cancer

The U.S. Food and Drug Administration (FDA) has approved the combination of durvalumab (Imfinzi, AstraZeneca) and Bacillus Calmette-Guérin (BCG) for adult patients with BCG-naive, high-risk non-muscle invasive bladder cancer (NMIBC). This marks the first immunotherapy combination therapy approved for this specific patient population, offering a significant advancement in treating a disease associated with high recurrence rates and potential progression to more invasive stages.

Key Trial Findings: The POTOMAC Study

The FDA’s decision was based on the phase 3 POTOMAC trial, which demonstrated a 32% reduction in the risk of disease recurrence, progression, or death for patients receiving durvalumab plus BCG compared to BCG alone. The open-label, multicenter trial enrolled 1,018 patients with high-risk NMIBC following transurethral resection of a bladder tumor (TURBT). Participants were randomly assigned 1:1:1 to one of three groups:

• Durvalumab (1,500 mg every 4 weeks for 13 cycles) plus BCG induction and maintenance
• BCG induction and maintenance alone
• An alternative investigational combination regimen

Patients treated with the durvalumab-BCG combination showed statistically significant improvements in disease-free survival (DFS) (hazard ratio [HR] = 0.68. 95% CI, 0.5–0.93) compared to those receiving BCG alone.

Treatment Protocol and Safety

The recommended dose of durvalumab for adults weighing at least 30 kg is 1,500 mg every 4 weeks for 13 cycles, in combination with BCG induction and maintenance. Treatment should be discontinued if high-risk disease recurs, progression occurs, or if unacceptable toxicity arises. The FDA has included warnings about immune-mediated adverse reactions, infusion-related reactions, and embryo-fetal toxicity in the prescribing information.

Expert Perspective: A New Hope for Patients

Meri-Margaret Deoudes, CEO of the Bladder Cancer Advocacy Network, emphasized the significance of the approval: “It is devastating for patients with high-risk non-muscle invasive bladder cancer to face the common, early and repeated disease recurrences that are the hallmark of this disease, let alone the prospect of progressing to more advanced disease and life-changing surgeries. New and effective treatment options that address their significant burden are always good news and are urgently needed.”

What This Means for Patients

This approval represents a critical step forward for patients with high-risk NMIBC, who often face a challenging prognosis with current standard-of-care therapies. The combination of durvalumab and BCG leverages the immune system’s potential to target cancer cells more effectively, reducing the likelihood of recurrence and progression.

Future Implications

As research continues, the integration of immunotherapy into bladder cancer treatment paradigms may redefine care for patients with NMIBC. Ongoing studies will further evaluate the long-term benefits and safety profiles of this approach, potentially expanding treatment options for those with limited alternatives.

Key Takeaways

• The FDA approved durvalumab plus BCG for BCG-naive, high-risk non-muscle invasive bladder cancer.
• The POTOMAC trial showed a 32% reduction in disease recurrence, progression, or death with the combination therapy.
• Treatment involves 13 cycles of durvalumab (1,500 mg every 4 weeks) plus BCG induction and maintenance.
• Immune-related adverse events and embryo-fetal toxicity are noted in the prescribing information.

For more information, visit the FDA’s official website or review the FDA press release.